阿帕替尼联合治疗复发难治性乳腺癌:2例病例报告及文献复习  

Combined treatment with apatinib for relapsed and refractory breast cancer:A report of 2 cases and related literature review

作　　者：张月明 徐海燕[2] 张凤春[1,2,3] 

机构地区：[1]徐州医科大学,江苏徐州221000 [2]上海交通大学医学院附属苏州九龙医院肿瘤科,江苏苏州215000 [3]上海交通大学医学院附属瑞金医院,上海200025

出　　处：《肿瘤》2017年第5期518-523,共6页Tumor

摘　　要：目的:观察阿帕替尼联合化疗或联合内分泌疗法治疗复发难治性乳腺癌的疗效及安全性。方法:报道2例复发难治性乳腺癌患者接受阿帕替尼联合化疗或内分泌治疗的疗效及安全性,并对相关文献进行复习。结果:2例患者均可评价疗效和不良反应,随访10个月,均达到疾病稳定。主要不良反应为高血压,使用降压药物后血压可以控制在正常范围内。结论:阿帕替尼联合化疗或内分泌治疗复发难治性乳腺癌的疗效肯定,不良反应可耐受。今后有待开展大样本的临床研究以进一步确认其疗效和安全性。Objective： To observe the efficacy and safety of apatinib combined with chemotherapy or endocrine therapy in the treatment of relapsed and refractory breast cancer. Methods： The clinical records of two patients with relapsed and refractory breast cancer treated with apatinib combined with chemotherapy or endocrine therapy were analyzed, and the related literatures were reviewed. Results： Two patients with relapsed and refractory breast cancer were treated with apatinib combined with chemotherapy or endocrine therapy and followed up for 10 months. The treatment outcome was stable disease. Major adverse reaction was hypertension, and the use of antihypertensive drugs could control the blood pressure in a normal range. Conclusion： Apatinib combined with chemotherapy or endocrine therapy in the treatment of relapsed and refractory breast cancer is effective, and the adverse effects are tolerated. Large-scale studies should be implemented to further determine the efficacy of this treatment protocol.

关 键 词：乳腺肿瘤 复发难治性乳腺癌 阿帕替尼 治疗结果 

分 类 号：R737.9[医药卫生—肿瘤]